主要研究目的：研究空腹/餐后状态下单次口服受试制剂美阿沙坦钾片与参比制剂美阿沙坦钾片（商品名：易达比® ；规格：40mg；Takeda Ireland Ltd.生产）在健康受试者体内的药代动力学，评价空腹/餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂美阿沙坦钾片（规格：40mg）与参比制剂易达比®（规格：40mg）在健康受试者中的安全性。

[Translation]

Primary study objective: To study the pharmacokinetics of the test preparation, Miasartan Potassium Tablets, and the reference preparation, Miasartan Potassium Tablets (trade name: Edabi®; specification: 40 mg; produced by Takeda Ireland Ltd.) in healthy subjects after a single oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary study objective: To evaluate the safety of the test preparation, Miasartan Potassium Tablets (specification: 40 mg) and the reference preparation, Edabi® (specification: 40 mg) in healthy subjects.

Start Date25 Feb 2025

Sponsor / Collaborator

Tianjin Huajin Pharmaceutical Co. Ltd.

CTR20244532

/ CompletedNot Applicable

美阿沙坦钾片在中国健康人群中餐后状态下单次给药的人体生物等效性临床试验

[Translation] A human bioequivalence clinical trial of Asartan Potassium Tablets after single administration in healthy Chinese people under the fed state

主要目的：以持证商为Takeda Pharma A/S的美阿沙坦钾片（商品名：易达比®（EDARBI®），规格：按美阿沙坦（C30H24N4O8）计80mg）为参比制剂，以杭州端本医药科技有限公司研发的美阿沙坦钾片（规格：按美阿沙坦（C30H24N4O8）计80mg）为受试制剂，评价两种制剂在中国健康受试者中餐后状态下的生物等效性。次要目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

Primary objective: To evaluate the bioequivalence of the two preparations in the postprandial state in healthy Chinese subjects, using the reference preparation of edartan potassium tablets (trade name: EDARBI®, specification: 80 mg based on edartan (C30H24N4O8)) developed by Hangzhou Duanben Pharmaceutical Technology Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Start Date25 Dec 2024

Sponsor / Collaborator

Hangzhou Duanben Pharmaceutical Technology Co., Ltd.

CTR20243804

/ CompletedNot Applicable

美阿沙坦钾片随机、开放、两周期、两序列、双交叉健康受试者餐后单次给药人体生物等效性试验

[Translation] A randomized, open-label, two-period, two-sequence, double-crossover bioequivalence study of Asartan potassium tablets in healthy subjects after a single dose after meal

主要目的：以健康受试者为试验对象，采用随机、开放、两周期、两序列、双交叉试验设计，考察健康受试者餐后单次口服山西德元堂药业有限公司生产的美阿沙坦钾片（受试制剂，规格：80mg）与Takeda Ireland Ltd.生产（Takeda Pharma A/S持证）的美阿沙坦钾片（参比制剂，商品名：易达比®，规格：80mg）后美阿沙坦的体内经时过程，估算其相关药代动力学参数及相对生物利用度，评价其餐后状态下的生物等效性，为受试制剂的生产注册申请提供依据。次要目的：评价美阿沙坦钾片受试制剂和参比制剂（商品名：易达比®）在健康受试者中的安全性。

[Translation]

Primary objective: To investigate the in vivo time course of Asartan Potassium Tablets (test preparation, specification: 80 mg) produced by Shanxi Deyuantang Pharmaceutical Co., Ltd. and Asartan Potassium Tablets (reference preparation, trade name: Edabi®, specification: 80 mg) produced by Takeda Ireland Ltd. (licensed by Takeda Pharma A/S) after a single oral administration of Asartan Potassium Tablets (test preparation, specification: 80 mg) to healthy subjects, estimate their relevant pharmacokinetic parameters and relative bioavailability, evaluate their bioequivalence in the postprandial state, and provide a basis for the production registration application of the test preparation. Secondary objective: To evaluate the safety of the test preparation and reference preparation of Asartan Potassium Tablets (trade name: Edabi®) in healthy subjects.

Start Date05 Nov 2024

Sponsor / Collaborator

Shanxi Deyuantang Pharmaceutical Co. Ltd.

100 Clinical Results associated with Azilsartan Kamedoxomil

100 Translational Medicine associated with Azilsartan Kamedoxomil

100 Patents (Medical) associated with Azilsartan Kamedoxomil

901

Literatures (Medical) associated with Azilsartan Kamedoxomil

01 May 2025·INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES

Bioinspired chitosan/PVA beads cross-linked with LTH-doped bacterial cellulose hydrochar for high-efficiency removal of antibiotics

Article

Author: Mosaffa, Elias ; Patel, Hima ; Ramsheh, Nasim Amiri ; Oroujzadeh, Mina ; Parekh, Kinnari ; Jamshidi, Edris ; Manteghi, Faranak ; Banerjee, Atanu

This study presents the development of eco-friendly, bioinspired Chitosan (CS)/Polyvinyl alcohol (PVA) composite beads cross-linked with layered triple hydroxide (LTH) doped bacterial cellulose microfilament (BCM) Hydrochar as a highly efficient adsorbent for removing Vancomycin (VAN) and Azithromycin (AZM) from aqueous solutions. The composite beads were synthesized using a bioinspired approach that integrates 1D BCM Hydrochar and 2D LTH plates into a 3D hybrid structure, offering high porosity, diverse functional groups, and pH sensitivity. The adsorbents were characterized using FTIR, EDX, SEM, XRD, and zeta potential analysis. Optimal adsorption conditions, including 60 min of contact time, 0.133 g·L^-1 dosage, and pH levels of 8 for VAN and 8.5 for AZM, achieved maximum adsorption capacities of 1845 mg·g^-1 for AZM and 2182 mg·g^-1 for VAN at a 500 mg·L^-1 concentration. The adsorption mechanisms involved physisorption and chemisorption, influenced by surface heterogeneity and interactions. VAN exhibited stronger adsorption, while AZM displayed more uniform adsorption due to weaker interactions. The adsorbent retained high adsorption capacity across multiple regeneration cycles and demonstrated resilience in the presence of coexisting compounds, making it suitable for long-term wastewater treatment. This work highlights the promise of carbohydrate-derived, sustainable LTH@BCM char-CS/PVA composite beads as high-capacity adsorbents, offering an effective, eco-friendly solution for mitigating pharmaceutical pollutants in water.

01 Apr 2025·Developmental Neurobiology

Azilsartan Confers Protection Against Kainic Acid–Induced Hippocampal Neuron Damage by Upregulating Sirt3/Sod2 Pathway

Article

Author: Lv, Hui‐hui ; Xia, Mao‐ying

ABSTRACT:

Epilepsy refers to a diverse group of neurological pathologies, coupled with a significant worldwide impact. Azilsartan, an angiotensin receptor blocker, is broadly applied as an antihypertensive medication. Considering that the neuroprotective potential of Azilsartan has been newly documented, our work was committed to characterizing the association of Azilsartan with epilepsy and its possible mechanism. First, mice hippocampal neuron (HT‐22) cells were exposed to kainic acid (KA) with or without Azilsartan treatment. Cell Counting Kit 8 (CCK8) method assessed the viability of KA‐treated HT‐22 cells. Flow cytometry assay was employed to detect cellular apoptotic capacity. DCF‐DA fluorescent staining, JC‐1 probe, and related assay kits were used to estimate mitochondrial oxidative stress. Western blotting examined the expression of Sirtuin 3 (Sirt3), superoxide dismutase 2 (Sod2), and apoptosis‐related proteins. Additionally, Sirt3 was silenced to analyze whether the protective effect of Azilsartan on KA‐induced damage of HT‐22 cell damage was achieved by regulating Sirt3. Results indicated that KA intervention concentration‐dependently triggered the viability loss, apoptosis, and mitochondrial damage in HT‐22 cells. Azilsartan treatment protected against KA‐induced HT‐22 cell injury by elevating the viability, reducing the apoptosis, and attenuating mitochondrial damage. Besides, Azilsartan administration activated Sirt3 and Sod2 expression in KA‐stimulated HT‐22 cells, and Sirt3 depletion partially blocked the impacts of Azilsartan on Sirt3/Sod2 pathway, mitochondrial damage, viability, and apoptosis in HT‐22 cells exposed to KA. Collectively, Azilsartan might act as a neuroprotective agent in treating epilepsy through the activation of Sirt3/Sod2 pathway.

01 Apr 2025·MICROBIAL PATHOGENESIS

Combinatory effects of chlorhexidine and azithromycin: Implications for therapeutic potential and mechanistic insights

Article

Author: Tunçer Çağlayan, Sinem

The use of drug combinations to re-sensitize resistant strains is a promising strategy to overcome the stagnation in the drug discovery pipeline. Here, the results demonstrate that the combined application of the broad-spectrum bisbiguanide antiseptic chlorhexidine (CHX) and the macrolide antibiotic azithromycin (AZM) significantly inhibits the growth of the Pseudomonas aeruginosa strain PAO1 (isolated from a wound) compared to the individual effects of each agent. Specifically, 1.5 μg/mL CHX caused 11.4 ± 4 % growth inhibition and 2 μg/mL AZM resulted in 14 ± 4.5 % inhibition; however, the combination of 1.5 μg/mL CHX and 2 μg/mL AZM achieved 58 ± 6 % inhibition, significantly exceeding the sum of their individual effects. Furthermore, the AZM and CHX combination reduced bacterial viability in biofilms. P. aeruginosa is a common pathogen in wounds, particularly chronic wounds, where it delays the healing process. An in vitro wound infection model further demonstrated that CHX and AZM combination reduced bacterial density and activity in a serum-supported collagen matrix. This combination was found to be effective not only against the Gram-negative P. aeruginosa but also against the Gram-positive Streptococcus mutans. To explain the observed combinatory inhibition effect mechanistically, Fourier Transform Infrared Spectroscopy (FTIR) was employed for the first time in the literature. The results reveal that CHX increases the cellular accumulation of AZM. Changes in the membrane lipid composition of the bacteria additionally suggest a mechanism for enhanced antibiotic accumulation in the presence of CHX. These findings suggest that the role of CHX as a potential partner in different syncretic combinations calls for comprehensive exploration in antibiotic resistant bacterial infections.

News (Medical) associated with Azilsartan Kamedoxomil

04 Nov 2019

·www.stada.com

STADA invests $660 Million USD in Takeda’s OTC portfolio in Russia/CIS to become a major player in these branded markets

Bad Vilbel, Moscow, November 5, 2019 – STADA Arzneimittel AG (together with its subsidiaries ‘STADA’ or ‘the Group’) has agreed to acquire a portfolio of selected products from Takeda Pharmaceutical Company Limited for a total value of $660 Million USD. The portfolio of approximately 20 selected over-the-counter (‘OTC’) and prescription pharmaceutical assets sold inter alia in Russia, Georgia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan will be divested to STADA Arzneimittel AG. The portfolio includes OTC-vitamins and food supplements, plus selected products within the cardiovascular, diabetes, general medicine, and respiratory therapeutic areas. Included in the transaction is the key product Cardiomagnyl, a well-known name and category leader in Russia, which is used to prevent blood clots, as well as the newer, patent-protected Nesina (for type II diabetes treatment) and Edarbi (angiotensin II receptor blocker for blood pressure control). The acquired portfolio complements STADA’s existing portfolio and capabilities in Russia which include medicines from 16 of 20 therapeutic groups of the best-selling products in retail pharmacies. The transaction will enable the Group to continue expanding its consumer health business in Russia and the CIS. It is expected that the highly capable approximately 500-strong sales and marketing team from Takeda’s business will transfer to STADA on completion of the transaction, which is expected in the first quarter of 2020. In addition, Takeda and STADA will enter into manufacturing and supply agreements in connection with the acquisition under which Takeda will continue to supply the products to STADA. The acquisition is expected to be financed by new debt financing. Peter Goldschmidt, CEO of STADA, commented: “This is STADA’s largest acquisition to date and will position us as a major player in a large and structurally growing market. This transaction also reflects the ambitions of STADA as we continue expanding the business internationally – both organically and through acquisitions – and continue generating significant operating efficiencies worldwide. STADA’s branded products are already well-represented in the most popular pharmacy categories in our key markets. However, we are continuing to expand our portfolio of branded generics, to strengthen our position in strategic niches and to develop new market segments.” Advisers to STADA on this transaction included: Nomura (M&A) and Kirkland & Ellis LLP (legal). About STADA Arzneimittel AG STADA Arzneimittel AG is headquartered in Bad Vilbel, Germany. The company focuses on a two pillar strategy consisting of generics, including specialty pharmaceuticals and non-prescription consumer health products. Worldwide, STADA Arzneimittel AG sells its products in approximately 120 countries. In financial year 2018, STADA achieved adjusted Group sales of EUR 2,330.8 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 503.5 million. As of December 31, 2018, STADA employed 10,416 people worldwide.

AcquisitionBiosimilar

26 Jul 2017

·www.bioportfolio.com

Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. [Report Updated: 20072017] Prices from USD $250

Summary Arbor Pharmaceuticals LLC Arbor is a healthcare products provider that develops prescription products for the hospital, cardiovascular and pediatric segments. The company offers licensing, manufacturing, development and commercialization of latestage prescription products. It also offers generic prescription and development stage products. Arbor's prescription products comprise edarbi, edarbyclor, bidil, nymalize, eryped, and erythromycin group of products. It offers products used in treatment areas including cardiovascular, emergency, pediatrics, psychiatry and endocrinology diseases. The company offers its products through sales professionals to hospitals and physicians across the US. Arbor is headquartered in Atlanta, Georgia, the US. Arbor Pharmaceuticals LLC Pharmaceuticals Healthcare Deals and Alliances Profile. provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company.

Acquisition

100 Deals associated with Azilsartan Kamedoxomil

External Link

KEGG	Wiki	ATC	Drug Bank
-	Azilsartan Kamedoxomil	C09CA09	DB08822

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Essential Hypertension	European Union	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	Iceland	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	Liechtenstein	Takeda Pharma A/S	07 Dec 2011
Essential Hypertension	Norway	Takeda Pharma A/S	07 Dec 2011
Hypertension	United States	Azurity Pharmaceuticals, Inc.	25 Feb 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	United States	Takeda Pharmaceutical Co., Ltd.	01 Jan 2012

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ESH2021	Not Applicable	Heart failure with normal ejection fraction \| Hypertension	-	Fixed-dose combination AZL-M/CLD	yoimflbcwh(evobzpjqnu) = nawsucinri zatbkyyniw (ybcxmzmtid, 8.7 - 12.3)	Positive	01 Apr 2021
				Non-fixed-dose combinations of iACE/ARB and thiazide/thiazide-like diuretics	yoimflbcwh(evobzpjqnu) = fkdfdzisql zatbkyyniw (ybcxmzmtid, 9.2 - 12.8)
NCT02541669 (CTgov)	Phase 1	Hypertension	64	TAK-491 (Open Label: TAK-491 40 mg)	qinmnrtypk(gkzipmdrrh) = hssoyfjxhd zqktqpotyw (tbvoioiymy, 25.0) View more	-	05 Feb 2020
				TAK-491 (Open Label: TAK-491 80 mg)	qinmnrtypk(gkzipmdrrh) = mqelnajadt zqktqpotyw (tbvoioiymy, 20.5) View more
NCT02517866 (CTgov)	Phase 4	Diabetes Mellitus, Type 2 \| Essential Hypertension	380	Azilsartan Medoxomil	ionkfbdfgs = oykslmqjzt xflgugzvhe (ivqkrcuwet, paezcvhuvm - oudmdudvgv) View more	-	01 Mar 2019
NCT02480764 (CTgov)	Phase 3	Essential Hypertension	612	Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	anxjvtfuwf(gexsmluinc) = fyqdqasfor esrhdfngks (tzjaxgereb, 0.5123) View more	-	11 Feb 2019
				Valsartan Placebo+Azilsartan medoxomil (Azilsartan Medoxomil 80 mg)	anxjvtfuwf(gexsmluinc) = dqmrrusuqv esrhdfngks (tzjaxgereb, 0.5010) View more
NCT00591773 (Pubmed \| J Renin Angiotensin Aldosterone Syst)	Phase 3	Essential Hypertension	551	Azilsartan medoxomil 40 mg plus chlorthalidone	wqsnfwmdqd(hapejmstjj) = mnxwnzmjdm snnmdmpwxp (tuwxjxtqot )	-	01 Jul 2018
				Azilsartan medoxomil 80 mg plus chlorthalidone	wqsnfwmdqd(hapejmstjj) = ilkowsjtbf snnmdmpwxp (tuwxjxtqot )
ESH2018	Not Applicable	Metabolic Syndrome \| Hypertension	32	Azilsartan medoxomil 40 mg	fiabswhrni(xsmccasimw) = uijblfdruf lciktjqeup (lyoizxmccm ) View more	Positive	01 Jun 2018
				Azilsartan medoxomil 80 mg	fiabswhrni(xsmccasimw) = gggyeepvpd lciktjqeup (lyoizxmccm ) View more
[PP.22.13] (ESH2017)	Not Applicable	Essential Hypertension	-	Azilsartan medoxomil 80 mg	uraivupxtl(typtihhwpf) = uqywmdbtws aybgfotryg (rzemujdkgc, 1.8) View more	Positive	01 Sep 2017
[PP.12.25] (ESH2017)	Not Applicable	Diabetes Mellitus, Type 2 \| Hypertension	30	Azilsartan medoxomil 40 mg	wgdmvivrzr(byxzzmmgnl) = lnqsntiewu ewnhzipmta (profwzhgqn )	Positive	01 Sep 2017
				Azilsartan medoxomil 80 mg	wgdmvivrzr(byxzzmmgnl) = vajifylxto ewnhzipmta (profwzhgqn )
NCT02203916 (CTgov)	Phase 3	Essential Hypertension	328	Azilsartan medoxomil placebo (Placebo)	iipvqpeyeg(qzgjwfshdj) = iflgutxywc rvjoyxhauq (gudprcjhmg, 2.0039) View more	-	19 Dec 2016
				Azilsartan medoxomil (Azilsartan Medoxomil 40 mg)	iipvqpeyeg(qzgjwfshdj) = mjooiugniy rvjoyxhauq (gudprcjhmg, 1.4117) View more
[PP.01.07] (ESH2016)	Not Applicable	Essential Hypertension	-	Azilsartan medoxomil 80 mg once-daily	xutyosywan(qvtqgejyip) = dqefyahfgb lducxejwwr (kljcvggllx, 1.8) View more	Positive	01 Sep 2016

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis